Drug profile · INN
ibalizumab
TROGARZO
ibalizumab (TROGARZO) is a t-cell surface antigen cd4 inhibitor.
EMA: withdrawn Antiinfectives for systemic use (J05) J05AX
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — ibalizumab
- Class
- Antiinfectives for systemic use (J05)
- Route
- —
- Patents
- 0
- Programs
- 0
- Data quality
- 0.83
Quick answer
ibalizumab (TROGARZO) is a t-cell surface antigen cd4 inhibitor.
Key facts
INN ibalizumab
Brand TROGARZO
Mechanism T-cell surface antigen CD4 inhibitor
Target T-cell surface glycoprotein CD4
Therapeutic class Antiinfectives for systemic use (J05)
ATC code J05AX
Mechanism of action
T-cell surface antigen CD4 inhibitor
Primary target: T-cell surface glycoprotein CD4
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | withdrawn | — |
Related & competitor drugs
Frequently asked questions
What is ibalizumab?
ibalizumab (TROGARZO) is a t-cell surface antigen cd4 inhibitor.
What is the brand name for ibalizumab?
TROGARZO is a marketed brand name for ibalizumab. Check FDA Drugs@FDA for the current US label holder and prescribing information.